Duchenne muscular dystrophy families are sharing stories about Elevidys complications on social media. But they aren’t ...

In another tragic incident, Sarepta Therapeutics (NASDAQ: SRPT) saw a second death in connection with its Duchenne muscular ...

WASHINGTON (AP) — Shares of Sarepta Therapeutics plunged Monday after the biotech drugmaker reported a second death in ...

Ticker: Second patient death reported with gene therapy for muscular dystrophy; Salmonella poisoning linked to pistachio ...

To date, over 900 Duchenne patients have been treated with delandistrogene moxeparvovec. "The signal for ALF is exceptionally rare and has only emerged in the non-ambulatory patients," Sarepta's CEO ...

Sarepta Therapeutics said a second patient had died after receiving its $3.2 million gene therapy to treat Duchenne muscular ...

Another gene therapy death of a Duchenne patient has some parents and doctors criticizing the FDA's actions, even as other ...

In the U.S., ELEVIDYS is indicated for the treatment of Duchenne muscular dystrophy (DMD ... You may also report side effects to Sarepta Therapeutics at 1-888-SAREPTA (1-888-727-3782).

CAMBRIDGE, Mass., May 13, 2025--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that the Japanese Ministry of ...

and the key Duchenne muscular dystrophy companies, including Santhera Pharmaceuticals, Sarepta Therapeutics, Italfarmaco, Wave Life Sciences Ltd, FibroGen, Edgewise Therapeutics, Pfizer ...

Sarepta's lead investigational gene therapy for Duchenne Muscular Dystrophy is under-appreciated by investors and should drive upside in the stock through 2019 and 2020. Management continues to ...

Duchenne Muscular Dystrophy has been linked to exon 51. Successful Manipulation of RNA And Dystrophin Using cutting-edge technology, Sarepta and Prosena designed compounds that induce skipping of ...